Abstract
BACKGROUND AND PURPOSE - : Reversal of anticoagulation with protamine might predispose to a higher risk of stroke in patients with carotid stenting. We evaluated a national, multihospital patient database to examine the risk of stroke in patients with carotid stenting receiving protamine compared with those who did not. METHODS - : The Premier Perspective database was used to identify patients who were electively hospitalized for carotid stenting from 2006 through 2011. The incidence of in-hospital mortality and morbidity was compared between patients who did and did not receive protamine after propensity score adjustment via 1:1 matching to reduce selection bias. RESULTS - : Of 6664 patients with carotid stenting treated at 193 hospitals, 556 (8%) received protamine on the day of the procedure. After matching by propensity score, patients who received protamine had a similar likelihood of stroke or transient ischemic attack (P=0.77), in-hospital mortality (P=0.12), discharge to long-term care (P=0.15), and access site complications (P=0.90) as compared with patients who did not receive protamine. CONCLUSIONS - : Protamine administration is not associated with additional risk of adverse events after carotid stenting. © 2013 American Heart Association, Inc.
Author supplied keywords
Cite
CITATION STYLE
McDonald, J. S., Kallmes, D. F., Lanzino, G., & Cloft, H. J. (2013). Protamine does not increase risk of stroke in patients with elective carotid stenting. Stroke, 44(7), 2028–2030. https://doi.org/10.1161/STROKEAHA.113.001188
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.